Skip to the main content

Croatian Medical Journal, Vol. 61 No. 2, 2020.

Original scientific paper

https://doi.org/10.3325/cmj.2020.61.93

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study

Zrinka Bukvić Mokos ; University of Zagreb School of Medicine, Zagreb, Croatia
Mikela Petković ; Department of Dermatovenereology, UniversityHospital Center Zagreb, Zagreb, Croatia
Anamaria Balić orcid id orcid.org/0000-0002-2673-8113 ; University of Zagreb School of Medicine, Zagreb, Croatia
Branka Marinović orcid id orcid.org/0000-0001-8441-5016 ; University of Zagreb School of Medicine, Zagreb, Croatia

Full text: english pdf 190 Kb

page 93-99

downloads: 460

cite

Abstract

Aim To evaluate the association between the use of dipeptidyl peptidase-4 inhibitors (DPP4I) and clinical and laboratory findings of bullous pemphigoid (BP) in patients treated at the European Reference Network – Skin Reference Centre in Croatia.
Methods This retrospective study enrolled 82 patients treated for BP at the Department of Dermatovenereology, University Hospital Center Zagreb from January 2015 to December 2019. Clinical features of BP, presence of comorbidities, and laboratory findings of anti-BP antibodies and eosinophilia were analyzed in three groups of BP patients: 1) diabetes mellitus (DM) type II patients treated with DPP4I, 2) DM type II patients not treated with DPP4I, and 3) non-DM type II patients. Results The average age and anti-BP180 titer were similar in all three groups. DPP4I group had a slightly lower eosinophil level in both peripheral blood (4.89%) and biopsy specimens (87.5%), but the difference was not significant. The prevalence of inflammatory BP in DPP4I group was 76.5%. DPP4I group had significantly higher percentage of patients with chronic renal failure and dementia (52.9% and 11.8%, respectively) compared with non-DPP4I DM (14.3% and 0%, respectively) and non-DM type II patients (15.7% and 0%, respectively).
Conclusion BP patients treated with DPP4I and those not treated with DPP4Is did not significantly differ in laboratory findings. However, DPP4I treatment was associated with an inflammatory subtype of BP and a higher prevalence of dementia and chronic renal failure. These findings warrant further research into the association of BP and DM with dementia and chronic renal failure.

Keywords

Hrčak ID:

240160

URI

https://hrcak.srce.hr/240160

Publication date:

15.4.2020.

Visits: 1.054 *